OBJECTIVES: The purpose of this article was to determine the incidence and predictors of vertebral fractures (VF) during the 4 years after diagnosis in pediatric acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: Children were enrolled within 30 days of chemotherapy initiation, with incident VF assessed annually on lateral spine radiographs according to the Genant method. Extended Cox models were used to assess the association between incident VF and clinical predictors. RESULTS: A total of 186 children with ALL completed the baseline evaluation (median age, 5.3 years; interquartile range, 3.4-9.7 years; 58% boys). The VF incidence rate was 8.7 per 100 person-years, with a 4-year cumulative incidence of 26.4%. The highest annual incidence occurred at 12 months (16.1%; 95% confidence interval [CI], 11.2-22.7), falling to 2.9% at 4 years (95% CI, 1.1-7.3). Half of the children with incident VF had a moderate or severe VF, and 39% of those with incident VF were asymptomatic. Every 10 mg/m(2) increase in average daily glucocorticoid dose (prednisone equivalents) was associated with a 5.9-fold increased VF risk (95% CI, 3.0-11.8; P < .01). Other predictors of increased VF risk included VF at diagnosis, younger age, and lower spine bone mineral density Z-scores at baseline and each annual assessment. CONCLUSIONS: One quarter of children with ALL developed incident VF in the 4 years after diagnosis; most of the VF burden was in the first year. Over one third of children with incident VF were asymptomatic. Discrete clinical predictors of a VF were evident early in the patient's clinical course, including a VF at diagnosis.
OBJECTIVES: The purpose of this article was to determine the incidence and predictors of vertebral fractures (VF) during the 4 years after diagnosis in pediatric acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: Children were enrolled within 30 days of chemotherapy initiation, with incident VF assessed annually on lateral spine radiographs according to the Genant method. Extended Cox models were used to assess the association between incident VF and clinical predictors. RESULTS: A total of 186 children with ALL completed the baseline evaluation (median age, 5.3 years; interquartile range, 3.4-9.7 years; 58% boys). The VF incidence rate was 8.7 per 100 person-years, with a 4-year cumulative incidence of 26.4%. The highest annual incidence occurred at 12 months (16.1%; 95% confidence interval [CI], 11.2-22.7), falling to 2.9% at 4 years (95% CI, 1.1-7.3). Half of the children with incident VF had a moderate or severe VF, and 39% of those with incident VF were asymptomatic. Every 10 mg/m(2) increase in average daily glucocorticoid dose (prednisone equivalents) was associated with a 5.9-fold increased VF risk (95% CI, 3.0-11.8; P < .01). Other predictors of increased VF risk included VF at diagnosis, younger age, and lower spine bone mineral density Z-scores at baseline and each annual assessment. CONCLUSIONS: One quarter of children with ALL developed incident VF in the 4 years after diagnosis; most of the VF burden was in the first year. Over one third of children with incident VF were asymptomatic. Discrete clinical predictors of a VF were evident early in the patient's clinical course, including a VF at diagnosis.
Authors: Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: Arthritis Care Res (Hoboken) Date: 2012-01 Impact factor: 4.794
Authors: A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward Journal: Arthritis Care Res (Hoboken) Date: 2010-04 Impact factor: 4.794
Authors: Meera S Rayar; Trishana Nayiager; Colin E Webber; Ronald D Barr; Uma H Athale Journal: Pediatr Blood Cancer Date: 2011-12-20 Impact factor: 3.167
Authors: Jinhui Ma; Kerry Siminoski; Nathalie Alos; Jacqueline Halton; Josephine Ho; Brian Lentle; MaryAnn Matzinger; Nazih Shenouda; Stephanie Atkinson; Ronald Barr; David A Cabral; Robert Couch; Elizabeth A Cummings; Conrad V Fernandez; Ronald M Grant; Celia Rodd; Anne Marie Sbrocchi; Maya Scharke; Frank Rauch; Leanne M Ward Journal: J Clin Endocrinol Metab Date: 2014-12-11 Impact factor: 5.958
Authors: Jacqueline Halton; Isabelle Gaboury; Ronald Grant; Nathalie Alos; Elizabeth A Cummings; Maryann Matzinger; Nazih Shenouda; Brian Lentle; Sharon Abish; Stephanie Atkinson; Elizabeth Cairney; David Dix; Sara Israels; David Stephure; Beverly Wilson; John Hay; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Bone Miner Res Date: 2009-07 Impact factor: 6.741
Authors: Ilaria Riccio; Marco Marcarelli; Nicola Del Regno; Claudia Fusco; Martina Di Martino; Raffaele Savarese; Giovanna Gualdiero; Matilde Oreste; Cristiana Indolfi; Giovanni Porpora; Marco Esposito; Fiorina Casale; Giovanni Riccardi Journal: J Pediatr Orthop B Date: 2013-05 Impact factor: 1.041
Authors: David R Weber; Alison Boyce; Catherine Gordon; Wolfgang Högler; Heidi H Kecskemethy; Madhusmita Misra; Diana Swolin-Eide; Peter Tebben; Leanne M Ward; Halley Wasserman; Christopher Shuhart; Babette S Zemel Journal: J Clin Densitom Date: 2019-07-10 Impact factor: 2.617
Authors: Etan Orgel; Nicole M Mueske; Richard Sposto; Vicente Gilsanz; Tishya A L Wren; David R Freyer; Anna M Butturini; Steven D Mittelman Journal: Leuk Lymphoma Date: 2017-02-20
Authors: J Ma; H J McMillan; G Karagüzel; C Goodin; J Wasson; M A Matzinger; P DesClouds; D Cram; M Page; V N Konji; B Lentle; L M Ward Journal: Osteoporos Int Date: 2016-10-24 Impact factor: 4.507
Authors: David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward Journal: Lancet Neurol Date: 2018-02-03 Impact factor: 44.182
Authors: Paula Aristizabal; Michael Sherer; Bianca P Perdomo; Esteban Castelao; Courtney D Thornburg; James Proudfoot; Elizabeth Jacobs; Ron S Newfield; Peter Zage; William Roberts; Maria Elena Martinez Journal: Pediatr Hematol Oncol Date: 2020-03-10 Impact factor: 1.969